Significantly, aberrant protein acetylation is recognised to take on an important role in driving the malignant phenotype [4]; thus, deregulation of HDAC activity occurs in different types of cancer and HDAC as a cancer drug target has been validated in many preclinical models [5]. This evidence concerns the gene HDAC9 and cancer.